Wednesday, 25 April 2018 - 19:19
  • it
  • de
  • en
  • fr


Novo’s Victoza, new indication to reduce CV risk

Novo Nordisk announced that the FDA approved a new indication for Victoza (liraglutide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes and cardiovascular disease. The indication is based on the results from the LEADER…